GU CONNECT expert, Assoc. Prof. Shilpa Gupta provides a urothelial cancer update from ASCO GU 2020 for you.


Urothelial cancer update by Assoc. Prof. Shilpa Gupta, University of Minnesota, Minneapolis, USA

 

Shilpa Gupta, MD is an Associate Professor in the Division of Hematology, Oncology and Transplantation and the lead for the Phase 1 Interdisciplinary Solid Tumor Program at the Masonic Cancer Center, University of Minnesota, Minneapolis, USA. Prior to joining the University of Minnesota in July 2015, Dr Gupta was faculty in Genitourinary Oncology and Experimental Therapeutics at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida for 4 years. Dr Gupta’s clinical and research interests are to treat patients with genitourinary malignancies and develop novel trials using targeted therapies and immunotherapies. She is currently the Principal investigator of several early and late phase trials in genitourinary oncology. Dr Gupta is passionate about her research and has published her research across a variety of peer-reviewed journals and book chapters. Twitter: @shilpaonc Email:guptash@umn.edu

Programme summary
Watch the video now
Other episodes of this series
GU CONNECT: Update from ASCO GU 2020

GU CONNECT: Update from ASCO GU 2020

Episode 1: Prostate Cancer
GU CONNECT Update from ASCO GU 2020

GU CONNECT Update from ASCO GU 2020

Episode 2: Urothelial Cancer Current Episode
GU CONNECT Update from ASCO GU 2020

GU CONNECT Update from ASCO GU 2020

Episode 3: Kidney Cancer
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update

Episode

3

of 3

episode
Oncology 
How are new data shaping the landscape in HER2-mutant NSCLC?

Insights from WCLC 2026

Experts
Dr Joshua Sabari
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • clock 5 MIN
  • calendar Sep 2026

Educational programme supported by an Independent Educational Grant from Bayer.
blueprint BluePrintInfographic / Flashcard
Oncology 
Biomarker testing in non-small cell lung cancer (NSCLC)

Insights from patients and caregivers

Experts
Prof. Christian Rolfo, Prof. Fernando López-Ríos, Dr Rodrigo Paredes de la Fuente, Anne-Marie Baird, Amy C. Moore, Shani Shilo
Endorsed by
LUNGevity The Israeli Lung Cancer Foundation
Biomarker Collaborative NTRKers Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology Hemato-oncology 
Myelofibrosis: Navigating unmet needs and overcoming clinical challenges

Expert perspectives on clinical trial highlights from EHA 2026

Experts
Prof. Francesco Passamonti, Prof. Claire Harrison
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Jul 2026

Brought to you by COR2ED Medical Affairs in collaboration with Menarini Stemline. This programme is intended for HCPS outside the UK. MED---2600258
micro-learning Micro learning - Video, slides and more
Oncology 
The evolving treatment landscape in HER2-mutant NSCLC

Expert insights on how the latest evidence is shaping clinical practice

Experts
Dr Devika Das, Dr Tom Newsom-Davis
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer